Does hCG or hCGβ play a role in cancer cell biology?

Molecular and Cellular Endocrinology

Volumn 329, Issue 1-2, 2010, Pages 62-70

  Iles, R K ^a   Delves, P J ^b   Butler, S A ^a  

^a MIDDLESEX UNIVERSITY   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Apoptosis; Cancer; Differentiation; HCG; HCG ; Oncogenesis

Indexed keywords

CHORIONIC GONADOTROPIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; CHORIONIC GONADOTROPIN VACCINE; GONADOTROPIN; NEUROTROPIN; NOGGIN; PLATELET DERIVED GROWTH FACTOR; RECOMBINANT CHORIONIC GONADOTROPIN; THYROTROPIN; TRANSFORMING GROWTH FACTOR BETA; TRASTUZUMAB; VASCULOTROPIN;

AMINO ACID SEQUENCE; APOPTOSIS; BREAST CANCER; CANCER CELL; CANCER GENE THERAPY; CARCINOGENESIS; CLINICAL TRIAL; COLORECTAL CANCER; CROSS REACTION; CYTOLOGY; DOWN REGULATION; EPITHELIUM TUMOR; GENE CLUSTER; GENE EXPRESSION; GENE FUNCTION; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SEQUENCE HOMOLOGY; STRUCTURAL HOMOLOGY; TREATMENT RESPONSE; X RAY CRYSTALLOGRAPHY;

ANIMALS; BREAST NEOPLASMS; CHORIONIC GONADOTROPIN; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; FEMALE; HUMANS; MICE; NEOPLASMS;

EID: 77957168150     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2010.07.014     Document Type: Review

References (109)

1. Agnantis N.J., Patra F., Khaldi L., Filis S. Immunohistochemical expression of subunit beta HCG in breast cancer. Eur. J. Gynaecol. Oncol. 1992, 13:461-466.
2. Arrieta O., Michel Ortega R.M., Angeles-Sánchez J., Villarreal-Garza C., Avilés-Salas A., Chanona-Vilchis J.G., Aréchaga-Ocampo E., Luévano-González A., Jiménez M.A., Aguilar J.L. Serum human chorionic gonadotropin is associated with angiogenesis in germ cell testicular tumors. J. Exp. Clin. Cancer Res. 2009, 28:120.
3. Ascheim S., Zondek B. Hypophysenworderlappen hormon und ovarialhormon im Harn von Schwangeren. Klin. Wochenschr. 1927, 6:1322-1324.
4. Ascheim C., Zondek B. Die Schwangerschaftsdiagnose aus dem Harn durch Nachweis der Hypophysevordem Lappenhormon. Klin. Wochenschr. 1928, 7:1404-1411.
5. Bagshawe K.D., Springer C.J., Searle F., Antoniw P., Sharma S.K., Melton R.G., Sherwood R.F. A cytotoxic agent can be generated selectively at cancer sites. Br. J. Cancer 1988, 58:700-703.
6. Barcellos-Hoff M.H., Ewan K.B.R. Transforming growth factor β and breast cancer: mammary gland development. Breast Cancer Res. 2000, 2:92-99.
7. Baselga J. Clinical trials of Herceptin(trastuzumab). Eur. J. Cancer 2001, 37(Suppl. 1):S18-24.
8. Berger P., Sturgeon C., Bidart J.M., Paus E., Gerth R., Niang M., Bristow A., Birken S., Stenman U.H. The ISOBM TD-7 workshop on hCG and related molecules. Towards user-oriented standardization of pregnancy and tumor diagnosis: assignment of epitopes to the three-dimensional structure of diagnostically and commercially relevant monoclonal antibodies directed against human chorionic gonadotropin and derivatives. Tumour Biol. 2002, 23:1-38.
9. Berzal-Cantalejo F., Sabater Marco V., Alonso Hernandez S., Jimenez Pena R., Martorell Cebollada M.A. Syncytial giant cell component, review of 55 renal cell carcinomas. Histol. Histopathol. 2004, 19:113-118.
10. Bhalang K., Kafrawy A.H., Miles D.A. Immunohistochemical study of the expression of human chorionic gonadotropin-beta in oral squamous cell carcinomas. Cancer 1999, 85:757-762.
11. Bieche I., Lazar V., Nogues C., Poynard T., Giovangrandi Y., Bellet D., Lidereau R., Vidaud M. Prognostic value of chorionic gonadotropin beta gene transcripts in human breast carcinoma. Clin. Cancer Res. 1998, 4:671-676.
12. Bodek G., Rahman N.A., Zaleska M., Soliymani R., Lankinen H., Hansel W., Huhtaniemi I., Ziecik A.J. A novel approach of targeted ablation of mammary carcinoma cells through luteinizing hormone receptors using Hecate-CGbeta conjugate. Breast Cancer Res. Treat. 2003, 79(May (1)):1-10.
13. Boucher L.D., Yoneda K. The expression of trophoblastic cell markers by lung carcinomas. Hum. Pathol. 1995, 26:1201-1206.
14. Butler S.A., Laidler P., Porter J.R., Kicman A.T., Chard T., Cowen D.A., Iles R.K. The β subunit of human chorionic gonadotrophin exists as a homodimer. J. Mol. Endocrinol. 1999, 22:185-192.
15. Butler S.A., Ikram M.S., Mathieu S., Iles R.K. The increase in bladder carcinoma cell population induced by the free β subunit of human chorionic gonadotrophin is a result of an anti-apoptosis effect and not cell proliferation. Br. J. Cancer 2000, 82:1553-1556.
16. Carlson H.E., Kane P., Lei Z.M., Li X., Rao C.V. Presence of luteinizing hormone/human chorionic gonadotropin receptors in male breast tissues. J. Clin. Endocrinol. Metab. 2004, 89:4119-4123.
17. Carter P.G., Iles R.K., Neven P., Ind T.E.J., Shepherd J.H., Chard T. Measurement of urinary β-core fragment of human chorionic gonadotrophin in women with vulvovaginal malignancy and its prognostic significance. Br. J. Cancer 1995, 71:350-353.
18. Chang E., Lee E., Oh S.J., Kim J.S., Kang C. The immunoexpressions and prognostic significance of inhibin alpha and Beta human chorionic gonadotrophins (HCG) in breast carcinomas. Cancer Res. Treat. 2005, 37:241-246.
19. Chen, Y., Kibriya, M.G., Jasmine, F., Santella, R.M., Senie, R.T., Ahsan, H., 2008. Do placental genes affect maternal breast cancer? Association between offspring's CGB5 and CSH1 gene variants and maternal breast cancer risk. Cancer Res., 68:9729-9734.
20. Chiesa M.D., Martensen P.M., Simmons C., Porakishvili N., Justesen J., Dougan G., Roitt I.M., Delves P.J., Lund T. Refocusing of B-cell responses following a single amino acid substitution in an antigen. Immunology 2001, 103:172-178.
21. Coombs L.M., Pigott D.A., Eydmann M.E., Proctor A.J., Knowles M.A. Reduced expression of TGFβ is associated with advanced disease in transitional cell carcinoma. Br. J. Cancer 1993, 67:578-584.
22. Crawford R.A., Iles R.K., Carter P.G., Caldwell C.J., Shepherd J.H., Chard T. The prognostic significance of human chorionic gonadotrophin and its metabolites in women with cervical carcinoma. J. Clin. Pathol. 1998, 51:685-688.
23. Daja M.M., Aghmesheh M., Ow K.T., Rohde P.R., Barrow K.D., Russell P.J. Beta-human chorionic gonadotropin in semen: a marker for early detection of prostate cancer?. Mol. Urol. 2000, 4:421-427.
24. Davies, S., 2001. Ectopic expression of glycoprotein hormones and their receptors by urogenital cancers, University of London, PhD Thesis.
25. de Bruijn H.W., ten Hoor K.A., Krans M., van der Zee A.G. Rising serum values of β-subunit human chorionic gonadotrophin (hCG) in patients with progressive vulvar carcinomas. Br. J. Cancer 1997, 75::1217-1218.
26. Delves P.J., Iles R.K., Roitt I.M., Lund T. Designing a new generation of anti-hCG vaccines for cancer therapy. Mol. Cell. Endocrinol. 2007, 260-262:276-281.
27. Devi G.R., Oldenkamp J.R., London C.A., Iversen P.L. Inhibition of human chorionic gonadotropin beta-subunit modulates the mitogenic effect of c-myc in human prostate cancer cells. Prostate 2002, 53:200-210.
28. Demir R., Kayisli U.A., Seval Y., Celik-Ozenci C., Korgun E.T., Demir-Weusten A.Y., Huppertz B. Sequential expression of VEGF and its receptors in human placental villi during very early pregnancy: differences between placental vasculogenesis and angiogenesis. Placenta 2004, 25:560-572.
29. Dirnhofer S., Koessler P., Ensinger C., Feichtinger H., Madersbacher S., Berger P. Production of trophoblastic hormones by transitional cell carcinoma of the bladder: association to tumor stage and grade. Hum. Pathol. 1998, 29:377-382.
30. Dirnhofer S., Freund M., Rogatsch H., Krabichler S., Berger P. Selective expression of trophoblastic hormones by lung carcinoma: neuroendocrine tumors exclusively produce human chorionic gonadotropin β-subunit (hCGβ). Hum. Pathol. 2000, 31:966-972.
31. El-Ahmady O., Halim A.B., Mansour O., Salman T., El-Din A.G., Walker R.P. Urinary gonadotropin peptide (UGP) in Egyptian patients with benign and advanced malignant urological disease. Br. J. Cancer 1996, 73:1486-1490.
32. Eder I.E., Stenzl A., Hobisch A., Cronauer M.V., Bartsch G., Klocker H. Transforming growth factors-β1 and β2 in serum and urine from patients with bladder carcinoma. J. Urol. 1996, 157:953-957.
33. Eder I.E., Stenzl A., Hobisch A., Cronauer M.V., Bartsch G., Klocker H. Expression of transforming growth factors-β1, β2 and β3 in human bladder carcinomas. Br. J. Cancer 1997, 75:1753-1760.
34. Fabisiewicz A., Kulik J., Kober P., Brewczynska E., Pienkowski T., Siedlecki J.A. Detection of circulating breast cancer cells in peripheral blood by a two-marker reverse transcriptase-polymerase chain reaction assay. Acta Biochim. Pol. 2004, 51:747-755.
35. Fujii D. Transforming growth factor β gene maps to human chromosome 19 long arm and to mouse chromosome 7. Somat. Cell Mol. Genet. 1986, 12:281-288.
36. Gebauer G., Fehm T., Beck E.P., Berkholz A., Licht P., Jager W. Cytotoxic effect of conjugates of doxorubicin and human chorionic gonadotropin (hCG) in breast cancer cells. Breast Cancer Res. Treat. 2003, 77:125-131.
37. Gillott D.J., lles R.K., Chard T. The effects of β-human chorionic gonadotrophin on the in vitro growth of bladder cancer cell lines. Br. J. Cancer 1996, 73:323-326.
38. Grossmann M., Hoermann R., Gocze P.M., Ott M., Berger P., Mann K. Measurement of human chorionic gonadotrophin-related immunoreactivity in serum, ascites and tumor cysts of patients with gynaecologic malignancies. Eur. J. Clin. Invest. 1995, 25:867-873.
39. Guo S., Russo I.H., Lareef M.H., Russo J. Effect of human chorionic gonadotropin in the gene expression profile of MCF-7 cells. Int. J. Oncol. 2004, 24:399-407.
40. Halim A.-B., El-Ahmady O., Hamza S., Aboul-Ela M., Oehr P. Urinary β-hCG in benign and malignant urinary tract disease. Dis. Markers 1995, 12:109-115.
41. Hansel W., Enright F., Leuschner C. Destruction of breast cancers and their metastases by lytic peptide conjugates in vitro and in vivo. Mol. Cell. Endocrinol. 2007, 260-262:183-189.
42. Hedstrom J., Grenman R., Ramsey H., Finne P., Lundin J., Haglund C., Alfthan H., Stenman U.H. Concentration of free hCGβ subunit in serum as a prognostic marker for squamous-cell carcinoma of the oral cavity and oropharynx. Int. J. Cancer 1999, 84:525-528.
43. Herr F., Baal N., Reisinger K., Lorenz A., McKinnon T., Preissner K.T., Zygmunt M. HCG in the regulation of placental angiogenesis. Results of an in vitro study. Placenta 2007, (Suppl. A):S85-S93.
44. Hoon D.S., Sarantou T., Doi F., Chi D.D., Kuo C., Conrad A.J., Schmid P., Turner R., Guiliano A. Detection of metastatic breast cancer by beta-hCG polymerase chain reaction. Int. J. Cancer 1996, 69:369-374.
45. Hotakainen K., Ljunberg B., Paju A., Rasmusen T., Althan H., Stenman U.H. The free beta subunit of human chorionic gonadotrophin as a prognostic factor in renal cell carcinoma. Br. J. Cancer 2002, 86:185-189.
46. Hotakainen K., Haglund C., Paju A., Nordling S., Alfthan H., Rintala E., Stenman U.H. Chorionic gonadotropin beta-subunit and core fragment in bladder cancer: mRNA and protein expression in urine, serum and tissue. Eur. Urol. 2002, 41:677-685.
47. Hotakainen K., Lintula S., Jarvinen R., Paju A., Stenman J., Rintala E., Stenman U.H. Overexpression of human chorionic gonadotropin beta genes 3, 5 and 8 in tumor tissue and urinary cells of bladder cancer patients. Tumour Biol. 2007, 28:52-56.
48. Hu Y.L., Lei Z.M., Huang Z.H., Rao C.V. Determinants of transcription of the chorionic gonadotropin/luteinizing hormone receptor gene in human breast cells. Breast J. 1999, 5:186-193.
49. Hu X.C., Chow L.W. Detection of circulating breast cancer cells with multiple-marker RT-PCR assay. Anticancer Res. 2001, 21:421-424.
50. Hu X.C., Loo W.T., Chow L.W. Surgery-related shedding of breast cancer cells as determined by RT-PCR assay. J. Surg. Oncol. 2003, 82:228-232.
51. Iles R.K., Butler S.A. Human urothelial carcinomas-a typical disease of the aged: the clinical utility of chorionic gonadotrophin in patient management and future therapy. Exp. Gerontol. 1998, 33:379-391.
52. Iles R.K., Chard T. Immunochemical analysis of the human chorionic gonadotrophin-like material secreted by 'normal' and neoplastic urothelial cells. J. Mol. Endocrinol. 1989, 2:107-112.
53. Iles R.K., Chard T. Human chorionic gonadotrophin expression by bladder cancers: biological and clinical potential. J. Urol. 1991, 145:453-458.
54. Iles R.K., Czepulkowski B.H., Young B.D., Chard T. Amplification and re-arrangement of the β-human chorionic gonadotrophin (β-hCG)-human LH gene cluster is not responsible for the ectopic production of β-hCG by bladder tumor cells. J. Mol. Endocrinol. 1989, 2:113-117.
55. Iles R.K., Lee C.L., Oliver R.T.D., Chard T. Composition of intact hormone and free subunits in the hCG-like material found in serum and urine of patients with carcinoma of the bladder. Clin. Endocrinol. 1990, 32:355-364.
56. Iles R.K., Purkis P.E., Whitehead P.C., Oliver R.T.D., Leigh I., Chard T. Expression of β human chorionic gonadotrophin by non-trophoblastic nonendocrine 'normal' and malignant epithelial cells. Br. J. Cancer 1990, 61:663-666.
57. Iles R.K., Persad R., Trivedi M., Sharma K.B., Dickinson A., Smith P., Chard T. Urinary concentration of human chorionic gonadotrophin and its fragments as a prognostic marker in bladder cancer. Br. J. Urol. 1996, 77:61-69.
58. Iles RK., 2007. Ectopic hCG beta expression by epithelial cancer: malignant behaviour, metastasis and inhibition of tumor cell apoptosis. Mol. Cell. Endocrinol. 260-262, 264-270.
59. Ind T., Iles R., Shepherd J., Chard T. Serum concentrations of cancer antigen 125, placental alkaline phosphatase, cancer-associated serum antigen and free β human chorionic gonadotrophin as prognostic markers for epithelial ovarian cancer. Br. J. Obstet. Gynaecol. 1997, 104:1024-1029.
60. Jackson A.M., Klonisch T., Lapthorn A.J., Berger P., Isaacs N.W., Delves P.J., Lund T., Roitt I.M. Identification and selective destruction of shared epitopes in human chorionic gonadotropin beta subunit. J. Reprod. Immunol. 1996, 31:21-36.
61. Jankowska A., Gunderson S.I., Andrusiewicz M., Burczynska B., Szczerba A., Jarmolowski A., Nowak-Markwitz E., Warchol J.B. Reduction of human chorionic gonadotropin beta subunit expression by modified U1 snRNA caused apoptosis in cervical cancer cells. Mol. Cancer 2008, 7:26.
62. Janssens J.P., Verlinden I., Gungor N., Raus J., Michiels L. Protein biomarkers for breast cancer prevention. Eur. J. Cancer Prev. 2004, 13:307-317.
63. Janssens J.P., Russo J., Russo I., Michiels L., Donders G., Verjans M., Riphagen I., Van den Bossche T., Deleu M., Sieprath P. Human chorionic gonadotropin (hCG) and prevention of breast cancer. Mol. Cell. Endocrinol. 2007, 269:93-98.
64. Jiang Y., Zeng F., Xiao C., Liu J. Expression of beta-human chorionic gonadotropin genes in renal cell cancer and benign renal disease tissues. J. Huazhong Univ. Sci. Technol. Med. Sci. 2003, 23:291-293.
65. Keler T., He L., Ramakrishna V., Champion B. Antibody-targeted vaccines. Oncogene 2007, 26:3758-3767.
66. Kido A., Mory M., Adachi Y., Yukaya H., Ishida T., Sugimachi K. Immunohistochemical expression of β-human chorionic gonadotropin in colorectal carcinoma. Surg. Today 1996, 26:966-970.
67. Kocdor H., Kocdor M.A., Russo J., Snider K.E., Vanegas J.E., Russo I.H., Fernandez S.V. Human chorionic gonadotropin (hCG) prevents the transformed phenotypes induced by [17] beta-estradiol in human breast epithelial cells. Cell Biol. Int. 2009, 33:1135-1143.
68. Lapthorn A.J., Harris D.C., Littlejohn A., Lustbader J.W., Canfield R.E., Machin K.J., Morgan F.K., Issacs N.W. Crystal structure of human chorionic gonadotrophin. Nature 1994, 369:455-461.
69. Li D., Wen X., Ghali L., Al-Shalabi F.M., Docherty S.M., Purkis P., Iles R.K. hCG beta expression by cervical squamous carcinoma-in vivo histological association with tumour invasion and apoptosis. Histopathology 2008, 53:147-155.
70. Louhimo J., Nordling S., Alfthan H., von Boguslawski K., Stenman U.H., Haglund C. Specific staining of human chorionic gonadotropin β in benign and malignant gastrointestinal tissues with monoclonal antibodies. Histopathology 2001, 38:418-424.
71. Louhimo J., Carpelan-Holmstrom M., Alfthan H., Stenman U.H., Jarvinen H.J., Haglund C. Serum hCG b, CA 72-4 and CEA are independent prognostic factors in colorectal cancer. Int. J. Cancer 2002, 101:545-548.
72. Louhimo J., Alfthan H., Stenman U.H., Haglund C. Serum hCG b and CA 72-4 are stronger prognostic factors than CEA, CA 19-9 and CA 242 in pancreatic cancer. Oncology 2004, 66:126-131.
73. Lundin M., Nording S., Carpelan-Holmstrom M., Louhimo J., Alfthan H., Stenman U.H., Haglund C. A comparison of serum and tissue hCG β as prognostic markers in colorectal cancer. Anticancer Res. 2000, 20:4949-4951.
74. Mann R.J., Keri R.A., Nilson J.H. Consequences of elevated luteinizing hormone on diverse physiological systems: use of the LHbetaCTP transgenic mouse as a model of ovarian hyperstimulation-induced pathophysiology. Recent Prog. Horm. Res. 2003, 58:343-375.
75. Meduri G., Charnaux N., Spyratos F., Hacene K., Loosfelt H., Milgrom E. Luteinizing hormone receptor status and clinical, pathologic, and prognostic features in patients with breast carcinomas. Cancer 2003, 97:1810-1816.
76. Mora J., Gascon N., Tabernero J.M., Rodriguez-Espinosa J., Gonzalez-Sastre F. Different hCG assays to measure ectopic hCG secretion in bladder carcinoma patients. Br. J. Cancer 1996, 74:1081-1084.
77. Moulton H.M., Yoshihara P.H., Mason D.H., Iversen P.L., Triozzi P.L. Active specific immunotherapy with a beta-human chorionic gonadotropin peptide vaccine in patients with metastatic colorectal cancer: antibody response is associated with improved survival. Clin. Cancer Res. 2002, 8:2044-2051.
78. Pectasides D., Bafaloucos D., Antoniou F., Gogou L., Economides N., Varthalitis J., Dimitriades M., Kosmidis P., Athanassiou A. TPA, TATI, CEA, AFP, β-hCG, PSA, SCC and CA 19-9 for monitoring transitional cell carcinoma of the bladder. Am. J. Clin. Oncol. 1996, 19:271-277.
79. Pierce J.G., Parsons T.F. Glycoprotein hormones: structure and function. Ann. Rev. Biochem. 1981, 50:465-495.
80. Pond-Tor S., Rhodes R.G., Dahlberg P.E., Leith J.T., McMichael J., Dahlberg A.E. Enhancement of radiosensitivity of the MCF-7 breast cancer cell line with human chorionic gonadotropin. Breast Cancer Res. Treat. 2002, 72:45-51.
81. Porakishvili N., Chiesa M.D., Chikadze N., Martensen P., Justesen J., Lund T., Delves P.J., Roitt I.M. Elimination of luteinizing hormone cross-reactive epitopes from human chorionic gonadotropin. Vaccine 2002, 20:2053-2059.
82. Rao ChV., Li X., Manna S.K., Lei Z.M., Aggarwal B.B. Human chorionic gonadotropin decreases proliferation and invasion of breast cancer MCF-7 cells by inhibiting NF-kappaB and AP-1 activation. J. Biol. Chem. 2004, 279:25503-25510.
83. Reisinger K., Baal N., McKinnon T., Münstedt K., Zygmunt M. The gonadotropins: tissue-specific angiogenic factors?. Mol. Cell. Endocrinol. 2007, 269:65-80.
84. Rull K., Laan M. Expression of beta-subunit of HCG genes during normal and failed pregnancy. Hum. Reprod. 2005, 20:3360-3368.
85. Ryan R.J., Charlesworth M.C., McCormick D.J., Milius R.P., Keutmann H.T. The glycoprotein hormones: recent studies of structure-function relationships. FASEB J. 1988, 11:2661-2669.
86. Salhab M., Al Sarakbi W., Mokbel K. In vitro fertilization and breast cancer risk: a review. Int. J. Fertil. Womens Med. 2005, 50:259-266.
87. Scholl P.D., Jurco S., Austin J.R. Ectopic production of β-hCG by a maxillary squamous cell carcinoma. Head Neck 1997, 19:701-705.
88. Schwarz-Roeger U., Petzoldt B., Waldschmidt R., Walker R.P., Bauknecht T., Kiechle M. UGP-a tumor marker of gynecologic and breast malignancies? Specificity and sensitivity in pretherapeutic patients and the influence of hormonal substitution on the expression of UGP. Anticancer Res. 1997, 17:3041-3045.
89. Shah T. Srirajaskanthan R. Bhogal M. Toubanakis C. Meyer T. Noonan A. Witney-Smith C. Amin T. Bhogal P. Sivathasan N. Warner B. Hochhauser D. Caplin M.E., 2008. α-Fetoprotein and human chorionic gonadotrophin-β as prognostic markers in neuroendocrine tumour patients. Br. J. Cancer 99, 72-77.
90. Sheaff M.T., Martin J.E., Badenoch D.F., Baithun S.I. βhCG as a prognostic marker in adenocarcinoma of the prostate. J. Clin. Pathol. 1996, 49:329-332.
91. Slodkowska J., Szturmowicz M., Rudzinski P., Giedronowicz D., Sakowicz A., Androsiuk W., Zakrzewska-Rowinska E. Expression of CEA and trophoblastic cell markers by lung carcinoma in association with histological characteristics and serum marker levels. Eur. J. Cancer Prev. 1998, 7:51-60.
92. Span P.N., Thomas C.M., Heuvel J.J., Bosch R.R., Schalken J.A., vd Locht L., Mensink E.J., Sweep C.G. Analysis of expression of chorionic gonadotrophin transcripts in prostate cancer by quantitative Taqman and a modified molecular beacon RT-PCR. J. Endocrinol. 2002, 172:489-495.
93. Span P.N., Manders P., Heuvel J.J., Thomas C.M., Bosch R.R., Beex L.V., Sweep C.G. Molecular beacon reverse transcription-PCR of human chorionic gonadotropin-beta-3, -5, and -8 mRNAs has prognostic value in breast cancer. Clin. Chem. 2003, 49:1074-1080.
94. Stenman U.H., Alfthan H., Hotakainen K. Human chorionic gonadotropin in cancer. Clin. Biochem. 2004, 37:549-561.
95. Syrigos K.N., Fyssas I., Konstandoulakis M.M., Harrington K.J., Papadopoulos S., Milingos N., Peveretos P., Golematis B.C. Beta human chorionic gonadotropin concentrations in serum of patients with pancreatic adenocarcinoma. Gut 1998, 42:88-91.
96. Szturmowicz M., Wiatr E., Sakowicz A., Slodkowska K., Filipecki S., Rowinska-Zakrzewska E.R. The role of human chorionic gonadotropin β subunit elevation in small-cell lung cancer patients. Tumor Biol. 1999, 20:99-104.
97. Taback B., Chan A.D., Kuo C.T., Bostick P.J., Wang H.J., Giuliano A.E., Hoon D.S. Detection of occult metastatic breast cancer cells in blood by a multimolecular marker assay: correlation with clinical stage of disease. Cancer Res. 2001, 61:8845-8850.
98. Talwar G.P. Vaccines and passive immunological approaches for the control of fertility and hormone-dependent cancers. Immunol. Rev. 1999, 171:173-192.
99. Tanaka Y., Kuwabara K., Okazaki T., Fujita T., Oizumi I., Kaiho S., Ogata E. Gonadotropins stimulate growth of MCF-7 human breast cancer cells by promoting intracellular conversion of adrenal androgens to estrogens. Oncology 2000, 59(Suppl. 1):19-23.
100. Vaitukaitis J.L., Braunstein G.D., Ross G.T. A radioimmunoassay which specifically measures human chorionic gonadotropin in the presence of human luteinizing hormone. Am. J. Obstet. Gynecol. 1972, 113:751-758.
101. Vartiainen J., Lassus H., Lehtovirta P., Finne P., Alfthan H., Butzow R., Stenman U.H. Combination of serum hCG beta and p53 tissue expression defines distinct subgroups of serous ovarian carcinoma. Int. J. Cancer. 2008, 122:2125-2129.
102. Webb A., Scott-Mackie P., Cunningham D., Norman A., Andreyev J., O'Brien M., Bensted J. The prognostic value of CEA, β HCG, AFP, CA125, CA19-9 and C-erb B-2, β hCG immunohistochemistry in advanced colorectal cancer. Ann. Oncol. 1995, 6:581-587.
103. Wu H., Lustbader J.W., Liu Y., Canfield R.E., Hendrickson W.A. Structure of human chorionic gonadotropin at 2.6Å resolution from MAD analysis of the selenomethionyl protein. Structure 1994, 15:545-558.
104. Wachner R., Wittekind C., von Kleist S. Immunohistological localization of beta-HCG in breast carcinomas. Eur. J. Cancer Clin. Oncol. 1984, 20:679-684.
105. Xie Y.B., Wang H., Segaloff D.L. Extracellular domain of lutropin/choriogonadotropin receptor expressed in transfected cells binds choriogonadotropin with high affinity. J. Biol. Chem. 1990, 265:21411-21414.
106. Yokotani T., Koizumi T., Taniguchi R., Nakagawa T., Isobe T., Yoshimura M., Tsubota H., Hasegawa K., Ohsawa N., Baba S., Yasui H., Nishimura R. Expression of α and β genes of human chorionic gonadotropin in lung cancer. Int. J. Cancer 1997, 71:539-544.
107. Zondek B. Versuch einer biologischen (hormonalen) Diagnostik beim malignen Hodentumor. Chirug 1930, 2:1072-1080.
108. Zondek B. Hormone des Ovariums und des Hypophysenvorderlappens 1935, Springer, Vienna, pp. 210-248.
109. Zygmunt M., Herr F., Keller-Schoenwetter S., Kunzi-Rapp K., Münstedt K., Rao C.V., Lang U., Preissner K.T. Characterization of human chorionic gonadotropin as a novel angiogenic factor. J. Clin. Endocrinol. Metab. 2002, 87:5290-5296.